NPS's 1Q Gattex sales disappoint, 2Q rebound under way
This article was originally published in Scrip
Executive Summary
NPS Pharmaceuticals admits that Gattex (teduglutide) sales grew at a slower-than-expected rate during the first quarter, but sales for the short bowel syndrome treatment increased by 17% compared with the fourth quarter of 2013 and sales are picking up in the second quarter.